JRSBRT 8.4, p. 275-282

Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer
Rashad Rzazade, Ngoc T.Pham, Menekse Turna, Mehmet Dogu Canoglu, Esra Kucukmorkoc, Kezban Berberoglu and Hale Basak Caglar

Objective: To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis (AGM) of oligometastatic lung cancer.

Methods: Between June 2013 and May 2021, 44 patients with oligometastatic lung cancer
(51 AGMs) were treated with SBRT. Forty-six (90%) lesions received a biological effective dose (BED10, α/β = 10) of 100 Gy. The primary endpoint was local control (LC). Local control (LC), overall survival (OS), and progression-free survival (PFS) curves were calculated by the Kaplan-Meier method.

Results: The median follow-up was 23 months. The most common histology was non-small cell lung cancer (88.6%). The 1- and 2-year LC rates were both 95% and 91%, respectively. Overall survival was better in patients with solitary AGMs in univariate analysis.

Conclusion: This study demonstrated that SBRT with higher BED is associated with satisfactory LC and low toxicity rates in patients with AGM of oligometastatic lung cancer.

Keywords: Stereotactic body radiotherapy, adrenal gland metastases, oligometastatic lung cancer, biologically effective dose